
    
      Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide
      pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on
      CYP2C9 genotype may improve antidiabetic treatment.
    
  